Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 31,68 € (+33,11 %). Medianen er 31,68 € (+33,11 %).

Køb	9
Behold	2
Sælg	0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

ZAI rises after strong half-year results and MSCI inclusion

ZAI’s stock rose 2.9% to HK$1,230 after the company reported revenue of RMB 954m, an increase of almost 400% year on year. The half-year loss narrowed, indicating margin improvement. Inclusion in the MSCI China Index triggers expected purchases by passive funds and broadens the institutional investor base, causing the stock to show strength against the falling Hang Seng. » Mere på de.investing.com
ZAI stock rises after Bernstein upgrade and speculation over GLM-5.5

ZAI shares climbed 8.4% on Wednesday to HK$1,095 after Bernstein initiated coverage with an “Outperform” and a HK$1,350 price target. The move followed a short-lived leak and withdrawal of documentation for the successor model GLM-5.3, which had already sparked a rally. Additional speculation about a potential flagship GLM-5.5, which JPMorgan expects to be released in August 2026, boosted investor sentiment; rival MiniMax, by contrast, received only a “Market Perform.” » Mere på de.investing.com
Zai Lab gains EMA orphan drug designation for DLL3‑targeting therapy

The European Medicines Agency granted orphan drug designation to zocilurtatug pelitecan (zoci), Zai Lab’s DLL3‑targeting antibody‑drug conjugate for pulmonary neuroendocrine carcinomas. The decision, backed by the EMA committee’s positive recommendation, reflects unmet need and early clinical data showing durable responses in relapsed or refractory extensive‑stage small cell lung cancer. The designation may bring development incentives and potential market exclusivity for Zai Lab. » Mere på finance.yahoo.com
Zai Lab shareholders approve all proposals at 2026 annual general meeting

Zai Lab shareholders voted in favor of all resolutions presented at the 2026 annual general meeting, including the re-election of several directors to serve until 2027 and the appointment of KPMG as independent auditors for the 2026 fiscal year. An advisory resolution on board compensation was approved. Shareholders also granted two general authorizations: one to issue or resell up to 10% of the issued ordinary shares/ADS and one to repurchase up to 10% of the issued ordinary shares/ADS until the 2027 annual general meeting. » Mere på de.investing.com
Zai Lab: president and COO Josh Smiley resigns

Zai Lab said Josh Smiley will resign as president and chief operating officer effective Monday; his last day is next Thursday. Smiley’s duties will be taken over by founder and CEO Samantha Du and other members of the leadership team. Smiley will receive a contractually agreed severance if he signs a customary release; the information comes from an 8‑K filing with the SEC. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Zai Lab en omsætning på 95,53 mio. € og et nettoresultat på -40,73 mio. €

(EUR)	september 2026	YoY
Omsætning	95,53 mio.	3,43 %
Bruttofortjeneste	50,24 mio.	14,82 %
Nettoresultat	-40,73 mio.	32,91 %
EBITDA	-40,99 mio.	56,89 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	2,66 mia. €
Antal aktier	112,81 mio.
Højeste/laveste i 52 uger	26,27 € - 14,45 €
Udbytte	Nej
Beta	0,83
P/E (PE Ratio)	-14,81
PEG (PEG Ratio)	-6,84
K/I (PB Ratio)	5,34
P/S (PS Ratio)	7,52

Virksomhedsprofil

Zai Lab Limited udvikler og kommercialiserer behandlinger til onkologi, autoimmune sygdomme, infektionssygdomme og neurovidenskab, primært i Kina (Mainland China) og Hongkong. Virksomhedens kommercielle produkter omfatter Zejula, en daglig småmolekylær poly polymerase 1/2-hæmmer; Optune, en enhed der leverer tumorbehandlende felter; NUZYRA til akutte bakterielle hud- og hudstrukturinfektioner samt samfundserhvervet bakteriel lungebetændelse; og Qinlock til behandling af gastrointestinale stromatumorer. Virksomheden udvikler også Odronextamab til behandling af follikulært lymfom, diffust storcellet B-celle-lymfom og andre B-celle-lymfomer; Repotrectinib, en tyrosinkinasehæmmer (TKI) rettet mod ROS1 og TRK A/B/C hos kræftpatienter, der er TKI-naive eller forbehandlet med TKI; Margetuximab til behandling af bryst- og gastroøsofageal kræft; Adagrasib til behandling af KRAS-G12C-muteret NSCLC, tyktarmskræft, bugspytkirtelkræft og andre solide tumorer; og Bemarituzumab til behandling af mave- og gastroøsofageal overgangskræft. Derudover udvikler virksomheden CLN-081 til behandling af patienter med EGFR exon 20-insertions-NSCLC; Elzovantinib, en oralt biotilgængelig multitargeteret kinasehæmmer; Tebotelimab, et tetravalent IgG4-monoklonalt antistof; Retifanlimab, der hæmmer interaktioner mellem PD-1 og dets ligander; ZL-2309, en oralt aktiv, selektiv og ATP-kompetitiv cellecyklus 7 (CDC7)-kinasehæmmer; ZL-1201, et humaniseret IgG4-monoklonalt antistof; Efgartigimod til at reducere sygdomsfremkaldende immunglobulin G-antistoffer; ZL-1102, en human nanobody rettet mod interleukin-17A; KarXT til behandling af psykiatriske og neurologiske tilstande; ZL-2313, en undersøgelseshæmmer af trippelmutant EGFR; ZL-2314, en undersøgelseshæmmer af dobbeltmutant EGFR; og Sulbactam/durlobactam til behandling af alvorlige infektioner forårsaget af Acinetobacter. Zai Lab Limited blev stiftet i 2013 og har hovedkontor i Shanghai, Kina.